Preferred Label : nadroparin;

MeSH definition : A heparin fraction with a mean molecular weight of 4500 daltons. It is isolated from porcine mucosal heparin and used as an antithrombotic agent. (From Merck Index, 11th ed);

MeSH synonym : nadroparin calcium; Nadroparine; calcium, nadroparin;

MeSH hyponym : fraxiparin; LMF CY-216; CY 216; Fraxiparine; CY-216; CY216; LMF CY 216; LMF CY216;

MeSH annotation : a low-molec weight heparin fraction;

Wikipedia link : https://en.wikipedia.org/wiki/Nadroparin calcium;

Is substance : O;

Details


Main resources

You can consult :

A heparin fraction with a mean molecular weight of 4500 daltons. It is isolated from porcine mucosal heparin and used as an antithrombotic agent. (From Merck Index, 11th ed)

https://www.has-sante.fr/jcms/p_3330890/fr/fraxiparine-nadroparine-calcique
2022
France
evaluation of the transparency committee
registries
nadroparin
fraxiparin

---
https://www.has-sante.fr/portail/jcms/c_2903180/fr/fraxiparine
https://www.has-sante.fr/portail/jcms/c_2903180/fr/fraxiparine-nadroparine-calcique-antithrombotique
2019
false
false
false
France
thromboembolism
mobility limitation
acute disease
nadroparin
treatment outcome
nadroparin
insurance, health, reimbursement
guidelines for drug use
evaluation of the transparency committee

---
https://www.has-sante.fr/portail/jcms/c_2773281/fr/fraxiparine
2017
false
false
false
France
French
evaluation of the transparency committee
nadroparin
nadroparin

---
http://www.has-sante.fr/portail/jcms/c_2642080/fr/fraxiparine
2016
false
false
false
France
French
evaluation of the transparency committee
nadroparin

---
http://www.has-sante.fr/portail/jcms/c_2642068/fr/fraxodi-fraxiparine
http://www.has-sante.fr/portail/jcms/c_1241658/fraxodi-fraxiparine
http://www.has-sante.fr/portail/jcms/c_455423/fr/fraxodi-fraxiparine
2016
false
France
French
nadroparin
anticoagulants
fibrinolytic agents
insurance, health, reimbursement
injections, subcutaneous
venous thrombosis
venous thromboembolism
postoperative complications
angina, unstable
myocardial infarction
nadroparin
renal dialysis
evaluation of the transparency committee

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=69766923
2008
France
French
Factor Xa Inhibitors
fibrinolytic agents
injections, subcutaneous
pharmaceutical solutions
nadroparin
nadroparin
factor xa
anticoagulants
anticoagulants
fibrinolytic agents
adult
venous thromboembolism
postoperative complications
venous thrombosis
renal dialysis
myocardial infarction
angina, unstable
drug approval
pregnancy
drug interactions
nadroparin
summary of product characteristics
package leaflet

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=66553941
2008
France
French
Factor Xa Inhibitors
fibrinolytic agents
injections, subcutaneous
pharmaceutical solutions
nadroparin
anticoagulants
fibrinolytic agents
anticoagulants
nadroparin
factor xa
drug approval
adult
venous thromboembolism
postoperative complications
venous thrombosis
renal dialysis
myocardial infarction
angina, unstable
pregnancy
drug interactions
nadroparin
summary of product characteristics
package leaflet

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60470990
2008
France
French
Factor Xa Inhibitors
fibrinolytic agents
injections, subcutaneous
pharmaceutical solutions
nadroparin
nadroparin
anticoagulants
anticoagulants
fibrinolytic agents
drug approval
factor xa
adult
venous thromboembolism
venous thrombosis
postoperative complications
renal dialysis
angina, unstable
myocardial infarction
drug interactions
pregnancy
nadroparin
summary of product characteristics
package leaflet

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=67617158
2008
France
French
Factor Xa Inhibitors
fibrinolytic agents
injections, subcutaneous
pharmaceutical solutions
nadroparin
nadroparin
anticoagulants
fibrinolytic agents
factor xa
drug approval
adult
postoperative complications
venous thromboembolism
renal dialysis
venous thrombosis
angina, unstable
anticoagulants
myocardial infarction
drug interactions
pregnancy
nadroparin
package leaflet
summary of product characteristics

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=64908308
2008
France
French
Factor Xa Inhibitors
injections, subcutaneous
pharmaceutical solutions
nadroparin
nadroparin
anticoagulants
anticoagulants
fibrinolytic agents
drug approval
venous thrombosis
fibrinolytic agents
thromboembolism
postoperative complications
drug therapy, combination
angina, unstable
myocardial infarction
renal dialysis
adult
drug interactions
pregnancy
factor xa
nadroparin
package leaflet
summary of product characteristics

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=62116606
2008
France
French
Factor Xa Inhibitors
fibrinolytic agents
drug approval
adult
postoperative complications
venous thromboembolism
venous thrombosis
renal dialysis
myocardial infarction
angina, unstable
drug interactions
pregnancy
fibrinolytic agents
injections, subcutaneous
pharmaceutical solutions
nadroparin
nadroparin
factor xa
anticoagulants
anticoagulants
nadroparin
package leaflet
summary of product characteristics

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60182657
2008
France
French
Factor Xa Inhibitors
fibrinolytic agents
injections, subcutaneous
pharmaceutical solutions
nadroparin
nadroparin
factor xa
anticoagulants
anticoagulants
fibrinolytic agents
drug approval
adult
venous thrombosis
continuity of patient care
drug monitoring
drug interactions
pregnancy
nadroparin
package leaflet
summary of product characteristics

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=63971056
2008
France
French
Factor Xa Inhibitors
fibrinolytic agents
injections, subcutaneous
pharmaceutical solutions
nadroparin
nadroparin
fibrinolytic agents
anticoagulants
anticoagulants
factor xa
adult
venous thrombosis
continuity of patient care
drug monitoring
drug approval
drug interactions
pregnancy
nadroparin
summary of product characteristics
package leaflet

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=68865128
2008
France
French
Factor Xa Inhibitors
pharmaceutical solutions
nadroparin
factor xa
anticoagulants
fibrinolytic agents
nadroparin
drug approval
adult
venous thrombosis
continuity of patient care
drug monitoring
pregnancy
drug interactions
anticoagulants
fibrinolytic agents
injections, subcutaneous
nadroparin
summary of product characteristics
package leaflet

---
http://www.has-sante.fr/portail/display.jsp?id=c_399496
2002
France
French
fibrinolytic agents
injections, subcutaneous
pharmaceutical solutions
nadroparin
anticoagulants
insurance, health, reimbursement
adult
venous thromboembolism
postoperative complications
venous thrombosis
renal dialysis
myocardial infarction
angina, unstable
nadroparin
anticoagulants
fibrinolytic agents
product surveillance, postmarketing
time
nadroparin
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/display.jsp?id=c_399294
2002
France
French
Factor Xa Inhibitors
nadroparin
fibrinolytic agents
venous thrombosis
anticoagulants
injections, subcutaneous
insurance, health, reimbursement
factor xa
nadroparin
evaluation of the transparency committee

---
Nous contacter.
26/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.